key: cord-0992482-phjcto9x
authors: Garibaldi, Brian T.; Wang, Kunbo; Robinson, Matthew L.; Zeger, Scott L.; Bandeen-Roche, Karen; Wang, Mei-Cheng; Alexander, G. Caleb; Gupta, Amita; Bollinger, Robert; Xu, Yanxun
title: Comparison of Time to Clinical Improvement With vs Without Remdesivir Treatment in Hospitalized Patients With COVID-19
date: 2021-03-24
journal: JAMA Netw Open
DOI: 10.1001/jamanetworkopen.2021.3071
sha: 2607e6cb04d84fc3ad4e24dfee5b6fa011ffe19d
doc_id: 992482
cord_uid: phjcto9x

IMPORTANCE: Clinical effectiveness data on remdesivir are urgently needed, especially among diverse populations and in combination with other therapies. OBJECTIVE: To examine whether remdesivir administered with or without corticosteroids for treatment of coronavirus disease 2019 (COVID-19) is associated with more rapid clinical improvement in a racially/ethnically diverse population. DESIGN, SETTING, AND PARTICIPANTS: This retrospective comparative effectiveness research study was conducted from March 4 to August 29, 2020, in a 5-hospital health system in the Baltimore, Maryland, and Washington, DC, area. Of 2483 individuals with confirmed severe acute respiratory syndrome coronavirus 2 infection assessed by polymerase chain reaction, those who received remdesivir were matched to infected individuals who did not receive remdesivir using time-invariant covariates (age, sex, race/ethnicity, Charlson Comorbidity Index, body mass index, and do-not-resuscitate or do-not-intubate orders) and time-dependent covariates (ratio of peripheral blood oxygen saturation to fraction of inspired oxygen, blood pressure, pulse, temperature, respiratory rate, C-reactive protein level, complete white blood cell count, lymphocyte count, albumin level, alanine aminotransferase level, glomerular filtration rate, dimerized plasmin fragment D [D-dimer] level, and oxygen device). An individual in the remdesivir group with k days of treatment was matched to a control patient who stayed in the hospital at least k days (5 days maximum) beyond the matching day. EXPOSURES: Remdesivir treatment with or without corticosteroid administration. MAIN OUTCOMES AND MEASURES: The primary outcome was rate of clinical improvement (hospital discharge or decrease of 2 points on the World Health Organization severity score), and the secondary outcome, mortality at 28 days. An additional outcome was clinical improvement and time to death associated with combined remdesivir and corticosteroid treatment. RESULTS: Of 2483 consecutive admissions, 342 individuals received remdesivir, 184 of whom also received corticosteroids and 158 of whom received remdesivir alone. For these 342 patients, the median age was 60 years (interquartile range, 46-69 years), 189 (55.3%) were men, and 276 (80.7%) self-identified as non-White race/ethnicity. Remdesivir recipients had a shorter time to clinical improvement than matched controls without remdesivir treatment (median, 5.0 days [interquartile range, 4.0-8.0 days] vs 7.0 days [interquartile range, 4.0-10.0 days]; adjusted hazard ratio, 1.47 [95% CI, 1.22-1.79]). Remdesivir recipients had a 28-day mortality rate of 7.7% (22 deaths) compared with 14.0% (40 deaths) among matched controls, but this difference was not statistically significant in the time-to-death analysis (adjusted hazard ratio, 0.70; 95% CI, 0.38-1.28). The addition of corticosteroids to remdesivir was not associated with a reduced hazard of death at 28 days (adjusted hazard ratio, 1.94; 95% CI, 0.67-5.57). CONCLUSIONS AND RELEVANCE: In this comparative effectiveness research study of adults hospitalized with COVID-19, receipt of remdesivir was associated with faster clinical improvement in a cohort of predominantly non-White patients. Remdesivir plus corticosteroid administration did not reduce the time to death compared with remdesivir administered alone.

This supplementary material has been provided by the authors to give readers additional information about their work.

Since the timing of initial remdesivir administration was different and the remdesivir assignment was nonrandomized, a time-dependent propensity score matching method was applied to undertake 1:1 propensity score matching for the treatment arm so that additional analyses could be performed on the matched patients. Propensity scores were calculated from a time-dependent Cox proportional hazards regression model using the time to the first receipt of remdesivir as the outcome, where the propensity score at a given hospitalization day is the hazard of exposure to remdesivir treatment at that day. The PH assumption was checked using the Schoenfeld residuals against the transformed time. [1] [2] Time-dependent covariates in records before the first remdesivir administration date (for treatment group patients) and records before right-censoring or last follow-up date (for control group patients) were used as predictors to obtain parameter estimates. Time-invariant (fixed) covariates included hospital admission race, age, sex, body mass index (BMI), Charlson comorbidity index (CCI), and code status (i.e. whether the patient had a "do not resuscitate" order). Time-dependent (varying) covariates included various clinical measures of disease severity, such as the ratio of measured oxygen saturation to fraction of inspired oxygen (SpO2/FiO2), systolic blood pressure (SBP), diastolic blood pressure (DBP), pulse, temperature, respiratory rate, and supplemental oxygen device (O2 device). SpO2/FiO2 was selected since it can be calculated without obtaining an arterial blood gas (not available on all patients). Other time-dependent variables included key laboratory test results, such as C-reactive protein (CRP), absolute lymphocyte count (ALC), platelets count, white blood cell count (WBC), hemoglobin (HGB), albumin, alanine aminotransferase (ALT), estimated Glomerular Filtration Rate (eGFR), and D-dimer.

Beginning from day zero, a sequential 1:1 greedy matching without replacement was conducted. Patients were included in the matching process only if their admission dates were later than the earliest admission date (April 27, 2020) of patients in the remdesivir group. A patient who first received remdesivir at a given day t of hospitalization was matched with those who did not, based on their propensity scores (hazard components) at day t. In addition, a time constraint was imposed so that a patient in the remdesivir group with k days of treatment, was forced to match a patient in the control group who stayed at least k days (5 days maximum) in the hospital since the matched day. This constraint removed patients from the control group who were healthy enough to be discharged in one or two days from the matched day as those patients were unlikely to receive remdesivir treatment at the matched day if they were close to discharge.

In sub-analyses considering the effects of combination drug use, comparisons of patients who used combination of corticosteroids and remdesivir (n=185) with patients who used remdesivir alone (n=158) were conducted. Since the sample sizes for two groups were similar, and patients' exposure to corticosteroids was timevariant, instead of time-dependent propensity score matching, Marginal Structural Cox regression models were conducted to adjust for the non-randomized administration of corticosteroids, in the meantime, to analyze the effects of corticosteroids on outcomes of interests in patients who had exposure to remdesivir. 3 The same set of timedependent covariates and time-invariant variables as in the matching models from all remdesivir patients were included in the model. The Inverse Probability Treatment Weighting (IPTW) method was applied for parameter estimation.

The primary outcome of interest was time to clinical improvement from the treatment start of remdesivir, defined as discharge alive from the hospital without worsening of their WHO disease severity score or at least a twopoint decrease in the WHO severity score during hospitalization within 28 days or max follow-up after the first treatment of remdesivir. Failure of clinical improvement was censored at max follow-up day or 28 days, whichever came first. Death was also censored at 28 days. The secondary outcome was time to death from the first remdesivir treatment day. Patients who were discharged alive were censored at 28 days. 

Propensity score matching with time-dependent covariates

Risk of death among users of Proton Pump Inhibitors: a longitudinal observational cohort study of United States veterans

Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men

Multivariate imputation by chained equations in R